Trial Profile
Safety and efficacy of ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin in patients with mixed cryoglobulinaemia and HCV infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Cryoglobulinaemia; Hepatitis C; Liver cirrhosis
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2017 New trial record